Evotec is advancing next-generation iPSC-derived CAR iγδ T cell therapies designed to deliver potent and sustained tumor clearance. By combining the natural anti-tumor properties of γδ T cells with customizable CAR engineering, immune-shielding technologies, and scalable GMP manufacturing, our platform addresses key challenges of today's cell therapies, including persistence, tumor microenvironment resistance, and accessibility. 

Download our factsheet to learn how Evotec's precision-engineered CAR iγδ T cell platform is shaping the future